drugset / Trial / NCT01047397

Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia

NCT01047397 ↗

Phase 2 Completed 107 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to characterize the safety and efficacy of repeat doses of compound 1278863A in subjects with anemia.

Timeline

Start
2010-03
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject 1278863A Small molecule 25 mg Oral
Subject 1278863A Small molecule 50 mg Oral
Subject 1278863A Small molecule 100 mg Oral

Indications